sales@angenesci.com
Login | Register
logo
Structures Search
Home Aminos (S)-N-(3-(3,4-Dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide

(S)-N-(3-(3,4-Dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide

CAS No.:
1616391-65-1
Catalog Number:
AG001VR4
Molecular Formula:
C20H25N5O3
Molecular Weight:
383.4442
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥95%
1 week
United States
$111
- +
5mg
99%
1 week
United States
$196
- +
10mg
99%
1 week
United States
$265
- +
50mg
99%
1 week
United States
$682
- +
100mg
99%
1 week
United States
$960
- +
Product Description
Catalog Number:
AG001VR4
Chemical Name:
(S)-N-(3-(3,4-Dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide
CAS Number:
1616391-65-1
Molecular Formula:
C20H25N5O3
Molecular Weight:
383.4442
MDL Number:
MFCD28411588
IUPAC Name:
N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide
InChI:
InChI=1S/C20H25N5O3/c26-17(10-25-6-5-14-3-1-2-4-15(14)9-25)8-21-20(27)18-7-19(23-13-22-18)24-16-11-28-12-16/h1-4,7,13,16-17,26H,5-6,8-12H2,(H,21,27)(H,22,23,24)/t17-/m0/s1
InChI Key:
ZKXZLIFRWWKZRY-KRWDZBQOSA-N
SMILES:
O[C@H](CN1CCc2c(C1)cccc2)CNC(=O)c1ncnc(c1)NC1COC1
Properties
Complexity:
518  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0
Exact Mass:
383.196g/mol
Formal Charge:
0
Heavy Atom Count:
28  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0
Molecular Weight:
383.452g/mol
Monoisotopic Mass:
383.196g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
99.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.8  
Literature
Title Journal
Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20150801
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cellular and molecular life sciences : CMLS 20150601
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood 20150416
Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells. Molecular oncology 20150301
PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer discovery 20150301
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing. The Journal of biological chemistry 20131206
Molecular pathways: protein methyltransferases in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 20131201
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. The EMBO journal 20070808
PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. The Journal of biological chemistry 20010831
Properties